Powder: -20°C for 3 years | In solvent: -80°C for 1 year
VPC-13163 (NSC-52361) has strong anti-proliferative activity against LNCaP and Enzalutamide-resistant prostate cancer cell lines (MR49F) whereas it did not affect the growth of AR independent PC3 cell line. It also inhibits Prostate Specific Antigen (PSA) in both LNCaP and MR49F and reduces expression of AR target genes, PSA and TMPRSS2. These findings suggest that VPC-13566 exhibits AR BF3 specific mechanism of action.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 137.00 | |
5 mg | In stock | $ 336.00 | |
10 mg | In stock | $ 497.00 | |
25 mg | In stock | $ 793.00 | |
50 mg | In stock | $ 1,130.00 | |
100 mg | In stock | $ 1,520.00 | |
500 mg | In stock | $ 2,970.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 295.00 |
Description | VPC-13163 (NSC-52361) has strong anti-proliferative activity against LNCaP and Enzalutamide-resistant prostate cancer cell lines (MR49F) whereas it did not affect the growth of AR independent PC3 cell line. It also inhibits Prostate Specific Antigen (PSA) in both LNCaP and MR49F and reduces expression of AR target genes, PSA and TMPRSS2. These findings suggest that VPC-13566 exhibits AR BF3 specific mechanism of action. |
Synonyms | 2,3-dihydro-2,3'-Bi-1H-indole, VPC13163, NSC52361, NSC 52361, VPC 13163 |
Molecular Weight | 234.3 |
Formula | C16H14N2 |
CAS No. | 6637-10-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 65 mg/ml (277.42 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
VPC-13163 6637-10-1 Others NSC-52361 2,3-dihydro-2,3'-Bi-1H-indole VPC13163 NSC52361 NSC 52361 VPC 13163 inhibitor inhibit